Botox Spasticity denied as non-formulary by Humana?

Humana's specific coverage criteria for botox spasticity are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies OnabotulinumtoxinA (Botox) for Spasticity as Non-Formulary — and How to Appeal

A non-formulary denial means that onabotulinumtoxinA (Botox) is not listed on Humana's drug formulary for the plan you are enrolled in, or is placed on a tier that requires additional authorization before coverage is triggered. For spasticity, this denial commonly occurs when Humana's formulary designates an alternative botulinum toxin product as the preferred agent, or when the drug is excluded from the specialty tier without a medical-necessity exception pathway.

Non-formulary denials are appealable through a formulary exception process, and they frequently succeed when the prescribing physician documents that the preferred or lower-tier alternative is clinically inappropriate for the specific patient.

## Federal Appeal Framework

ACA §2719 requires non-grandfathered plans to offer both internal appeal and external review. ERISA §503 governs self-funded plans. In addition to the standard appeal path, you may simultaneously request a formulary exception — a parallel administrative process that bypasses the formulary restriction rather than overturning the denial. Both tracks are worth pursuing. The external review window is approximately four months from the final internal denial. Request expedited review if the patient's condition warrants urgency.

## Concrete Appeal Steps and Timeline

1. Request Humana's formulary exception form and the plan's published formulary for your benefit year. Identify the preferred alternative Humana expects to be tried first. 2. File a formulary exception request simultaneously with or before the formal internal appeal, supported by the prescriber's letter. 3. If the exception is denied, file a Level 1 internal appeal within the deadline on the denial notice. 4. If Level 1 fails, proceed to Level 2 or IRO external review. 5. For ACA marketplace plans, the formulary exception process must be decided within 72 hours on an expedited basis or within a standard timeframe set by your state.

## Documentation to Gather

• Diagnosis confirmation: chart documentation of the underlying neurological condition and affected muscle groups
• Prior treatment history: records of any preferred or alternative botulinum toxin products tried — with dates, outcomes, and documented clinical response or failure
• Clinical rationale for Botox specifically: prescriber letter explaining why the preferred formulary alternative is clinically inappropriate for this patient (e.g., prior adverse reaction, inadequate response, diffusion profile requirements for specific muscle groups)
• Clinical severity: functional assessments and spasticity documentation from the chart
• Prescriber medical-necessity letter explicitly addressing the formulary exception criteria

## Criteria-Mapping Structure

Humana's formulary exception policy will list what the physician must demonstrate. Address each in the letter:

| Formulary Exception Criterion | Prescriber Response | |---|---| | Preferred alternative tried and failed | [Alternative product name, dates of trial, documented outcome] | | Preferred alternative clinically contraindicated | [Clinical basis — e.g., prior adverse reaction or specific patient characteristic] | | Medical necessity of the non-formulary drug | [Mechanism or clinical property that makes Botox specifically appropriate] | | Supporting diagnosis and functional impairment | [ICD-10 code, spasticity severity, functional limitation] |

A clear formulary exception letter that directly addresses each criterion — rather than a generic narrative — is the single most important factor in reversing this denial type.